Stopping Trazodone: What Patients Experience, What Providers Should Know, and How to Do It Safely

In clinical practice, a great deal of attention is devoted to starting an antidepressant. The decision to prescribe, the choice of agent, the initial dose, the titration schedule—these are topics covered extensively in prescribing guidelines, patient handouts, and follow-up appointments. Far less attention, in many cases, is paid to the other end of the journey: stopping.

For patients on trazodone, this gap in the clinical conversation can have real consequences. While trazodone is not classified as a controlled substance and does not carry the same physiological dependence profile as benzodiazepines or opioids, abrupt discontinuation or poorly managed tapering can produce a range of uncomfortable symptoms that are both predictable and largely preventable. Understanding what those symptoms are, why they occur, and how to avoid them is not a secondary concern—it is a fundamental part of responsible prescribing.

Why People Stop Trazodone

Patients discontinue trazodone for a variety of reasons, and the clinical approach to stopping may differ depending on which of those reasons applies.

Some patients reach a point of sustained remission and, in collaboration with their provider, make the informed decision that continued pharmacotherapy is no longer necessary. Others stop because of side effects—excessive sedation, orthostatic hypotension, or morning grogginess that interferes with daily functioning. Still others discontinue because they are transitioning to a different antidepressant, or because they are pregnant or planning to become pregnant. In some cases, patients stop on their own without consulting their provider, either because they feel well or because they have concerns about long-term use.

Each of these scenarios carries its own clinical considerations, but all of them share a common principle: the manner in which trazodone is discontinued matters.

Dependence vs. Withdrawal: Getting the Language Right

A persistent source of confusion—for both patients and, at times, providers—is the distinction between physical dependence and addiction. Trazodone does not produce the craving, drug-seeking behavior, or compulsive use that characterize addiction. However, the body does adapt to the chronic presence of any centrally acting medication, and that adaptation can manifest as physiological symptoms when the drug is removed.

This is referred to as discontinuation syndrome, and it is a well-recognized phenomenon across the antidepressant class. It does not indicate that a patient is "addicted" to their medication. It indicates that the nervous system has recalibrated itself around the drug's presence, and that recalibration takes time to reverse.

For trazodone specifically, the discontinuation syndrome tends to be less severe than that associated with SSRIs or SNRIs—particularly paroxetine or venlafaxine, which have a well-documented and sometimes intense withdrawal profile. Nevertheless, some patients do experience notable symptoms, and those symptoms deserve to be taken seriously rather than minimized.

What Discontinuation May Actually Feel Like

Patients who stop trazodone abruptly or taper too quickly may report a constellation of symptoms that can begin within days of dose reduction. These commonly include:

• Sleep disruption. Because trazodone is frequently prescribed for its sedative properties—whether as a primary indication or as an off-label sleep aid—its removal often triggers rebound insomnia. Sleep quality may deteriorate noticeably, sometimes more severely than the original insomnia the medication was managing. This is one of the most commonly reported discontinuation experiences.
• Irritability and mood instability. Some patients describe heightened emotional reactivity, low-grade anxiety, or a return of depressive symptoms during the tapering period. Distinguishing between discontinuation-related mood symptoms and genuine relapse of the underlying condition is a critical clinical task.
• Dizziness and flu-like sensations. These are characteristic of antidepressant discontinuation broadly and may include lightheadedness, nausea, and a general sense of malaise.
• Sensory disturbances. Some patients report unusual sensations sometimes described as "brain zaps"—brief electrical-feeling pulses—though this phenomenon is more commonly associated with SSRI discontinuation than with trazodone specifically.

The severity and duration of these symptoms vary considerably between individuals and are influenced by the dose at which the patient was taking trazodone, the duration of treatment, and the speed of tapering.

Tapering Protocols: Evidence and Practical Guidance

No universally standardized tapering protocol for trazodone exists in published guidelines, which means that clinical judgment and individualized planning are essential. The general principle, however, is consistent across the literature: slower is safer.

For patients who have been taking trazodone at typical antidepressant doses (150 mg to 400 mg daily), a gradual dose reduction over several weeks to months is generally recommended. A common approach involves reducing the total daily dose by approximately 25 to 50 mg every one to two weeks, pausing if significant discontinuation symptoms emerge and resuming the taper only after the patient has stabilized.

For patients using trazodone at lower doses primarily for sleep (typically 25 mg to 100 mg nightly), the taper can often be accomplished more quickly, though even in this population, abrupt cessation may produce noticeable rebound insomnia.

Several practical considerations are worth incorporating into any tapering plan:

• Timing matters. Reducing the dose during a period of relative stability—not during a major life stressor, illness, or transition—reduces the risk of conflating discontinuation symptoms with relapse.
• Document the baseline. Before beginning a taper, both provider and patient should have a shared understanding of what the patient's symptoms looked like prior to starting trazodone. This creates a reference point for distinguishing withdrawal effects from underlying condition recurrence.
• Build in check-ins. Scheduled follow-up contacts—whether in-person or via telehealth—during the tapering period allow early identification of symptoms that may warrant slowing the process.
• Address sleep proactively. For patients who relied on trazodone primarily for its sedative effect, a plan for managing rebound insomnia should be established before the taper begins. This might include behavioral interventions such as cognitive behavioral therapy for insomnia (CBT-I), sleep hygiene reinforcement, or, in some cases, a temporary alternative sleep aid.

The Patient's Role in a Safe Discontinuation

Healthcare providers cannot manage a taper they are not aware of. One of the most important messages for patients is this: do not stop trazodone without telling your prescriber. Even if the decision to stop feels straightforward—perhaps you feel well, or you are concerned about side effects—your provider needs to be part of that conversation to help you do it safely.

Patients should also be encouraged to keep a brief daily log during the tapering period. Tracking sleep quality, mood, energy levels, and any new physical symptoms provides a far more accurate picture than memory alone and helps both the patient and provider make informed decisions about the pace of the taper.

If symptoms become difficult to manage, it is appropriate—and not a sign of failure—to temporarily return to a previous dose and slow the taper. Discontinuation is not a test of willpower. It is a medical process, and like any medical process, it may require adjustment.

When Stopping Is the Right Decision, It Deserves a Plan

Trazodone has helped a great many patients in the United States manage depression, anxiety, and insomnia. When the time comes to step away from it, that transition deserves the same clinical thoughtfulness that initiated the therapy. A structured, unhurried taper—grounded in honest communication between patient and provider—is not an afterthought. It is the final, essential chapter of a responsible treatment course.